CHEK2 anticorps (N-Term)

N° du produit ABIN309588

Détail du produit anti-CHEK2 anticorps

Antigène: CHEK2 (Checkpoint Kinase 2 (CHEK2))

Épitope: N-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CHEK2 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Séquence: MSRESDVEAQ QSHGSSACSQ PHGSVTQSQG SSSQSQGISS SSTSTMPNSS

Homologie: Human: 100%

Attributs du produit: This is a rabbit polyclonal antibody against CHEK2. It was validated on Western Blot using a cell lysate as a positive control.

Purification: Affinity Purified

Immunogène: The immunogen is a synthetic peptide directed towards the N terminal region of human CHEK2

Information d'application

Indications d'application: Optimal working dilutions should be determined experimentally by the investigator.

Commentaires:

Antigen size: 514 AA

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

Références pour anticorps anti-CHEK2 (ABIN309588)

Yomo, Hongo, Kuroyanagi, Kobayashi: "Parkinsonism and midbrain dysfunction after shunt placement for obstructive hydrocephalus." dans: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, Vol. 13, Issue 3, pp. 373-8, (2006) (PubMed).

Détails sur CHEK2

Antigène: CHEK2 (Checkpoint Kinase 2 (CHEK2))

Autre désignation: CHEK2 (CHEK2 Produits)

Synonymes: anticorps CDS1, anticorps CHK2, anticorps HuCds1, anticorps LFS2, anticorps PP1425, anticorps RAD53, anticorps hCds1, anticorps fa66f08, anticorps wu:fa66f08, anticorps zgc:55865, anticorps Cds1, anticorps HUCDS1, anticorps Rad53, anticorps Chk2, anticorps cds1, anticorps chek2, anticorps chk2, anticorps hucds1, anticorps lfs2, anticorps pp1425, anticorps rad53, anticorps checkpoint kinase 2, anticorps serine/threonine-protein kinase chk2, anticorps checkpoint kinase 2 L homeolog, anticorps CHEK2, anticorps chek2, anticorps Chek2, anticorps MCYG_07308, anticorps chek2.L

Sujet: In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. CHEK2 is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, CHEK2 is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in its gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in its gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases.In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.
Alias Symbols: RP11-436C9.1, CDS1, CHK2, HuCds1, LFS2, PP1425, RAD53, hCds1
Protein Interaction Partner: SRPK1, PPP2CA, PLK1, CHEK2, PRKDC, ATM, POLR2L, RCHY1, VHL, UBC, NR4A1, ELAVL1, CDC25A, ARHGAP1, PER3, CDC25C, CUL1, CUL4A, KPNA2, APP, STRAP, TP53, BRCA1, RB1, DAPK3, UBR5, PML, MDM2, BRCA2, KAT2B, LATS2, PSME3, TRIM28, RNF8, STAT1, PPP2R5E, PPP2R5D, PPP
Protein Size: 514

Poids moléculaire: 58 kDa

ID gène: 11200

NCBI Accession: NM_145862, NP_665861

Pathways: Signalisation p53, Apoptose, Cycle Cellulaire